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Introduction {#sec005}
============

Among antiretrovirals approved for the treatment of HIV-1 infection, maraviroc and the recently approved ibalizumab are unique in targeting a host protein rather than a viral enzyme. By engaging the transmembrane helices of the CC chemokine receptor 5 (CCR5), maraviroc disrupts the geometry of the multi-point interaction between the second extracellular loop of CCR5 and the V3 loop of HIV-1 glycoprotein (gp) 120, allosterically preventing R5 virus from binding. As a result of the targeted mode of action, a tropism test demonstrating the presence of CCR5-tropic (R5) virus is a prerequisite for maraviroc use. During clinical development, tropism was determined with the Trofile phenotypic test provided by Monogram Biosciences (CA, USA). Subsequently, largely retrospective validation studies established genotypic tropism testing as an alternative, based on the analysis of the gp120 V3 sequence through an automated predictive algorithm, most commonly the geno2pheno\[coreceptor\] system \[[@pone.0225381.ref001]\]. Comparative evaluations demonstrated a good albeit not perfect technical correlation between phenotypic and genotypic tropism testing \[[@pone.0225381.ref002]--[@pone.0225381.ref004]\]. Importantly, genotypic tropism testing was found to predict virological outcome within both retrospective evaluations of clinical trial data and in observational cohorts \[[@pone.0225381.ref002],[@pone.0225381.ref005]--[@pone.0225381.ref007]\].

The efficacy and safety of maraviroc have been demonstrated in phase 3 clinical trials of both antiretroviral treatment (ART)-naïve and ART-experienced subjects with R5 virus \[[@pone.0225381.ref008]--[@pone.0225381.ref012]\]. While in the US maraviroc is approved for both indications, in Europe it is approved only for the treatment of ART-experienced subjects. In clinical practice, however, maraviroc has been used in a variety of clinical scenarios \[[@pone.0225381.ref013]--[@pone.0225381.ref018]\].

With the aim of gaining a comprehensive understanding of maraviroc use, this multicentre observational cohort study surveyed reasons for starting maraviroc and measured the efficacy and durability of maraviroc-containing regimens across Europe. A secondary objective was to determine the performance of genotypic tropism testing in relation to virological outcomes.

Patients and methods {#sec006}
====================

Study population and data collection {#sec007}
------------------------------------

Subjects eligible for inclusion were HIV-1 positive adults who started their first maraviroc-containing ART regimen between January 2005 and December 2013 within routine clinical practice, and had ≥1 follow-up visit after receiving ≥1 dose of maraviroc. Fully anonymised data available from individual electronic databases and clinical cohorts were collected as part of a formal European audit of clinical service; no ethics permission was required, and the audit was registered with the Royal Liverpool University Hospital in the United Kingdom. A total of 26 clinical cohorts in 8 European countries participated. Each centre adhered to local research governance regulations concerning the collection and analysis of routinely collected, anonymised clinical data for audit purposes. Data submission to the central audit repository occurred through a structured case record form that collected simple demographic data (age, gender, ethnicity), current and nadir CD4 cell count, CD4 cell count and plasma HIV-1 RNA load at the start of maraviroc (baseline, measured within 6 weeks prior to starting maraviroc) and during follow-up, ART history (number and classes of antiretrovirals received prior to baseline, calendar year of first maraviroc use, reasons for starting and stopping maraviroc, and antiretrovirals used together with maraviroc), results of drug resistance and tropism testing performed at any time before and after starting maraviroc, and HIV-1 subtype if known. We used objective measures from the database in order to classify the context of maraviroc use. ART-naïve patients were classified on the objectively verified absence of previous ART use. In ART-experienced individuals, treatment was classified as "ART switch" when one or more components of the existing regimen were changed alongside the introduction of maraviroc, and as "ART intensification" when maraviroc was added as a single agent to the existing regimen. These treatment categories were subdivided based on suppressed or detectable viral load (i.e., HIV-1 RNA either \< or ≥ 50 copies/mL) prior to maraviroc initiation.

Viral tropism and drug susceptibility {#sec008}
-------------------------------------

Results of genotypic tropism testing were verified by a centralised re-analysis of gp120 V3 sequences using geno2pheno\[coreceptor\] version 2.5 \[[@pone.0225381.ref001]\] with a false positive rate (FPR) defining R5-tropic virus set at \>10% in case of triplicate sequences or \>20% in case less than three sequences were available, as per published European guidelines \[[@pone.0225381.ref019]\]. Centres using phenotypic testing submitted results obtained with the Monogram Trofile or Enhanced Sensitivity Trofile assay. A valid baseline tropism assay result was measured using plasma collected within 90 days prior to starting maraviroc in viraemic patients. Older results obtained from either plasma, whole blood or peripheral blood mononuclear cells (PBMC) where accepted provided the patient had not experienced viraemia between the tropism test and the start of maraviroc, as per European guidelines \[[@pone.0225381.ref019]\]. The Genotypic Susceptibility Score (GSS) of the regimen accompanying maraviroc was derived from protease, reverse transcriptase, and integrase sequences using the Stanford's HIVdb 8.1 algorithm ([www.hivdb.stanford.edu](http://www.hivdb.stanford.edu/)), whereby each drug in the regimen was assigned a susceptibility score based on the estimated levels of drug resistance: susceptible and potential low-level resistance = 1; low-level and intermediate resistance = 0.5; and high-level resistance = 0. For enfuvirtide, gp41 sequences were interpreted using HIV GRADE (<http://www.hiv-grade.de/grade/deployed/grade.pl?program=hivalg>). In the absence of an integrase or gp41 sequence, integrase inhibitors and enfuvirtide were assumed to be fully active in case of first use or previous use without failure (score = 1) and not active (score = 0) in case of previous use with documented failure. HIV-1 subtypes were assigned based on all *pol* sequences using the Rega subtyping tool 3.0 (<http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool>) and the Comet algorithm (<https://www.ncbi.nlm.nih.gov/pubmed/25120265>). In case of discordant results between the two algorithms, the subtype was set as undetermined.

Treatment outcomes for maraviroc-containing regimens and statistical analysis {#sec009}
-----------------------------------------------------------------------------

The date of maraviroc initiation was considered the baseline for the study. Treatment outcomes were measured over 48 weeks (allowing a window of +/- 6 weeks). Treatment failure (TF) was defined by either virological failure (VF, viral load \>50 copies/mL while on maraviroc) or maraviroc discontinuation prior to week 48 for any cause. The VF analysis comprised patients who remained on maraviroc at week 48. Time to maraviroc discontinuation was estimated by survival analysis using the Kaplan-Meier method; where data were available past week 48, these were retained in the analysis. Predictors of TF and VF were analysed by univariate and multivariable logistic regression. All p-values were calculated by a univariate mixed logistic model taking into account the clustering effect of the clinical centre. In the multivariable models, a backward stepwise selection method was employed starting from a model with all variables showing an association with the outcome of interest with a p-value ≤ 0.2 according to the univariate analysis. These models employed a stepwise exclusion criterion of variables with p-values \>0.2, except for viral tropism that was manually included in all models. In the final multivariable models, all variables retained by the selection method were simultaneously adjusted. Statistical analysis was performed using the STATA version 13.0 software package.

Results {#sec010}
=======

Study population at baseline {#sec011}
----------------------------

Data were retrieved from 26 clinical centres in 8 countries totalling 1,381 patients, and comprising 538 from the United Kingdom and Ireland, 291 from Italy, 259 from Germany, 206 from Spain, 43 from France, 30 from Belgium, and 14 from Luxemburg. The characteristics of the study population at the time of starting maraviroc (baseline) are summarized in [Table 1](#pone.0225381.t001){ref-type="table"}. Most patients were males of white ethnicity (718/1,381, 52%), 754/1,381 (54.6%) with a nadir CD4 count \<200 cells/mm^3^, and 782/1,381 (56.6%) with a current CD4 cell count ≥350 cells/mm^3^. Almost half (630/1,381, 45.6%) had a suppressed viral load (\<50 copies/mL). The overall cohort was heavily ART-experienced, with 718/1,381 (52.0%) having received ≥7 antiretroviral drugs and about two-thirds (926/1,381, 67.1%) having experienced ≥3 drug classes including protease inhibitors (PIs) in 1213/1,381 (87.8%) and integrase inhibitors in 651/1,381 (47.1%).

10.1371/journal.pone.0225381.t001

###### Characteristics of the study population at the start of maraviroc (n = 1,381).

![](pone.0225381.t001){#pone.0225381.t001g}

  ----------------------------------------------------------------------------------
  Characteristic                                                             
  ----------------------------------------------- ----------------- -------- -------
  **Age, median years (IQR)**                     46                41--52   

  **Males, n (%)**                                1,052             76.7%    

  **Ethnicity, n (%)**                            White Caucasian   718      52.0%

                                                  Black African     231      16.7%

                                                  Asian             18       1.3%

                                                  Other/Unknown     414      30.0%

  **Nadir CD4 count**\                            \<50              285      20.6%
  **(cells/mm**^**3**^**)**\                                                 

  50--199                                         469               34.0%    

  200--349                                        290               21.0%    

  ≥350                                            148               10.7%    

  NA                                              189               13.7%    

  **Baseline CD4 count (cells/mm**^**3**^**)**\   \<50              51       3.7%

  50--199                                         236               17.1%    

  200--349                                        257               18.6%    

  ≥350                                            782               56.6%    

  NA                                              55                4.0%     

  **HIV-1 RNA**\                                  \<50              630      45.6%
  **(copies/mL)**                                                            

  50--199                                         147               10.6%    

  200--4,999                                      253               18.3%    

  5,000--99,999                                   189               13.7%    

  ≥100,000                                        120               8.7%     

  NA                                              42                3.0%     

  **Prior antiretrovirals, n (%)**\               \<3               268      19.4%

  3--6                                            341               24.7%    

  7--10                                           349               25.3%    

  ≥10                                             369               26.7%    

  NA                                              54                3.9%     

  **Prior drug classes, n (%)**                   \<3               455      32.9%

                                                  3                 482      34.9%

                                                  ≥3                444      32.2%

  **PI experienced, n (%)**                       1,213             87.8%    

  **NRTI experienced, n (%)**                     1,249             90.4%    

  **NNRTI experienced, n (%)**                    846               61.3%    

  **InSTI experienced, n (%)**                    651               47.1%    

  **Enfuvirtide experienced, n (%)**              84                6.1%     

  **Calendar year**\                              2005--2008        249      18.0%
  **of maraviroc start**\                                                    

  2009--2010                                      496               35.9%    

  2011                                            311               22.5%    

  2012--2016                                      325               23.5%    
  ----------------------------------------------------------------------------------

Abbreviations: ART, antiretroviral treatment; NA, not available; PI, protease inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; InSTI, integrase strand-transfer inhibitor.

Viral tropism {#sec012}
-------------

Tropism assay results were available for 1,273 (92.3%) participants: 1,075 through genotypic testing and 189 through a phenotypic assay (Trofile in 118, Enhanced Sensitivity Trofile in 58, unspecified in 13). In 9 cases the type of assay was not specified and no V3 sequences were available for re-analysis. Both phenotypic and genotypic tropism assay results were available in 14 cases, with only one discordant case where the phenotypic result was considered. Tropism testing was performed using plasma HIV-1 RNA in 696 cases and HIV-1 DNA (from whole blood or PBMC) in 561; in 16 cases the source was not specified. The tropism result was R5 in 1,049/1,273 (82.4%) and non-R5 in 224/1,273 (17.6%). The FPR results were available for 1,036/1,075 genotypic tropism assays and comprised: \<10% in 104 cases, 10% to 20% in 133 cases, 20% to 40% in 249 and ≥40% in 550 cases. The median FPR value (IQR) was 50.5 (33.9--78.1) for results assigned as R5 and 10.4 (4.6--15.5) for those assigned as non-R5.

GSS and HIV-1 subtypes {#sec013}
----------------------

The GSS of the regimen accompanying maraviroc was available for 661/1,381 (47.9%) subjects, including 393/709 (55.4%) subjects that started maraviroc with HIV-1 RNA ≥50 copies/mL. The GSS was \<1 in 83/661 (12.6%), 1 in 254/661 (38.4%), 2 in 228/661 (34.5%), and ≥3 in 96/661 (14.5%). The viral subtype was available in 794/1,381 patients (57.5%): most carried subtype B (606/794, 76.3%), followed by C (36, 4.5%), A (33, 4.2%), CRF02_AG (19, 2.4%), G (12, 1.5%), others (43, 5.4%), and unassigned subtype (45, 5.7%).

Patterns of maraviroc use {#sec014}
-------------------------

Clinician-reported reasons for maraviroc initiation were available in 1,297/1,381 (93.9%) patients. Most patients that started maraviroc were described as treatment experienced. Among the reported reasons, VF accounted for 547/1,297 (39.6%) initiations, whereas a change of a virologically suppressive regimen was reported in 465/1,297 (35.9%) as a result of toxicity (374, 27.1%) or other reasons (91, 6.6%). Intensification of suppressive ART was described in 104/1,297 (8.0%) subjects and the reasons comprised low CD4 cell counts (56, 4.1%) and miscellaneous other reasons including aiming to improve ART activity in the central nervous system (CNS). Maraviroc was started in ART-naïve subjects in 49/1,297 (3.5%) cases. For the remaining 132/1,297 (9.6%) subjects, the reason for maraviroc initiation was not reported. For analytic purposes, the context of maraviroc initiation was classified using objective measures ([Table 2](#pone.0225381.t002){ref-type="table"}). Among the 1,381 patients with an objectively classifiable reason for maraviroc initiation, 882 (63.9%) switched ART regimen (i.e., added maraviroc while stopping and/or adding at least another agent), comprising 441 (31.9%) with a detectable viral load, 409 (29.6%) with an undetectable viral load and 32 (2.3%) with unknown viral load. The existing ART regimen was intensified with maraviroc as a single add-on agent in 101/1,381 (7.3%) subjects, comprising 50 (3.6%) with a detectable viral load, 50 (3.6%) with an undetectable viral load, and 1 (0.1%) with unknown viral load. ART-naïve maraviroc use accounted for 46/1,381 (3.3%) cases.

10.1371/journal.pone.0225381.t002

###### Context of maraviroc use.

![](pone.0225381.t002){#pone.0225381.t002g}

  --------------------------------------------------------------------------
  ART status                           HIV-1 RNA\    n     \% of all cases
                                       (copies/mL)         
  ------------------------------------ ------------- ----- -----------------
  **Starting ART from naive**          \>50          46    3.3%

  **Switching ART regimen**            \<50          409   29.6%

                                       ≥50           441   31.9%

                                       NA            32    2.3%

  **Intensification of ART regimen**   \<50          50    3.6%

                                       ≥50           50    3.6%

                                       NA            1     0.1%

  **Unknown**                          \<50          169   12.2%

                                       ≥50           175   12.7%

                                       NA            8     0.6%
  --------------------------------------------------------------------------

Abbreviations: ART, antiretroviral treatment; NA, not available

The most frequently employed total daily dose of maraviroc was reported as 300mg (733/1,381, 53.1%), followed by 600mg (228/1,381, 16.5%), 150mg (167/1,381, 12.1%) and 1,200mg (31/1,381, 2.2%); the dose was not reported in 222/1,381 (16.1%) of cases. The dosing schedule was reported as twice daily in 661/1,381 (47.9%) subjects, once daily in 276/1,381 (20.0%), and was not reported in 444/1,381 (32.2%). The accompanying drugs belonged to 1, 2, and 3 or more classes in 518/1,381 (40.2%), 626/1,381 (45.3%) and 144/1,381 (10.4%) regimens, respectively ([Table 3](#pone.0225381.t003){ref-type="table"}); 906 (70.4%) regimens included PIs.

10.1371/journal.pone.0225381.t003

###### Antiretroviral treatment classes used with maraviroc.

![](pone.0225381.t003){#pone.0225381.t003g}

  -----------------------------------------------------
  Number\             Class                n     \%
  of classes                                     
  ------------------- -------------------- ----- ------
  **1**               Any                  518   37.5

                      PI                   333   24.1

                      NRTI or NNRTI        161   11.7

                      InSTI                20    1.4

                      2 PIs                4     0.3

  **2**               Any                  626   45.3

                      NRTI + PI            111   8.0

                      2--3 NRTIs + PI      192   13.9

                      NRTI + NNRTI         39    2.8

                      1--2 NRTIs + 2 PIs   2     0.1

                      Other combination    282   20.4

  **3**               Any                  120   8.7

                      PI + NRTI + NNRTI    13    0.9

                      Other combination    107   7.7

  **4**               Any                  24    1.7

  **Not available**   93                   6.7   
  -----------------------------------------------------

Abbreviations: PI, protease inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor

NNRTI, non-nucleoside reverse transcriptase inhibitor; InSTI, integrase strand-transfer inhibitor.

Treatment outcomes of maraviroc containing regimens {#sec015}
---------------------------------------------------

Duration of follow-up and number of visits differed from centre to centre because of varying clinical practice. Several sites provided only data covering 48 weeks after maraviroc initiation, whereas others reported all available follow-up. During 1,845 person-years of follow-up, maraviroc was discontinued in 354 patients. The survival analysis ([Fig 1](#pone.0225381.g001){ref-type="fig"}) showed a stable rate of maraviroc discontinuation during the first 2 years, with a 1-year estimated probability of continuing maraviroc of 82.1% (95% CI, 79.9--84.2). Durability was estimated based on patients continuing to receive maraviroc, regardless of VF. Reasons for maraviroc discontinuation were reported for 294 patients and comprised VF (92/294, 31.4%), treatment simplification (27/294, 9.3%), clinician's decision (29/294, 9.8%), toxicity (53/294, 18.1%), non-adherence (37/294, 12.7%), patient's choice (10/294, 3.4%), non-R5 tropism (6/294, 2.0%), loss to follow-up (6/294, 2.0%), death (6/294, 2.0%), and other reasons (27/294, 9.3%). Reported toxicity reasons comprised two cases of serum transaminases elevation.

![Kaplan-Meier curve of the cumulative probability of continuing maraviroc after its initiation in the study cohort.\
The line indicates the estimate, shadows represent the 95% confidence intervals. MVC, maraviroc. The number of patients receiving maraviroc are indicated as "Number at risk". The vertical line shows the 48 weeks cut-off point; all available data up to 24 months of follow-up were used.](pone.0225381.g001){#pone.0225381.g001}

Overall, 572/1,381 (41.4%, 95% CI: 38.9--44.1) subjects experienced TF over 48 weeks of follow-up. The logistic regression analysis of factors associated with TF is shown in [Table 4](#pone.0225381.t004){ref-type="table"}. After adjustment, the odds of TF were increased by a low nadir CD4 count, a detectable baseline viral load, having previously experienced PI therapy, a non-R5 tropism result, a GSS of the regimen accompanying maraviroc ≥3 and starting maraviroc after 2011. There was also a marginal effect of age.

10.1371/journal.pone.0225381.t004

###### Univariate and multivariable logistic regression analysis of factors associated with treatment failure over 48 weeks.

![](pone.0225381.t004){#pone.0225381.t004g}

                                                 Univariate analysis   Multivariablee analysis                                                                                 
  ---------------------------------------------- --------------------- ------------------------- ------ -------------------------------------------- ------------ ------------ --------
  **Age (years)**                                \<35                  151                       50.3   0.04                                         1.00                      0.05
  ≥35                                            1212                  40.1                             0.68[^a^](#t004fn004){ref-type="table-fn"}   0.46--0.99                
  35--44                                         458                   38.0                                                                                                    
  45--54                                         532                   42.7                                                                                                    
  ≥55                                            222                   38.3                                                                                                    
  **Ethnicity**                                  White Caucasian       718                       40.8   0.17                                         NI                         
  Black African                                  231                   42.9                                                                                                    
  Asian                                          18                    33.3                                                                                                    
  Other                                          29                    51.7                                                                                                    
  **Nadir CD4 count (cells/mm**^**3**^**)**      \<50                  285                       51.9   \<0.01                                       1.00                       
  50--199                                        469                   41.4                             0.70                                         0.50--0.97   0.03         
  200--349                                       290                   39.7                             0.73                                         0.51--1.05   0.09         
  ≥350                                           148                   35.1                             0.48                                         0.30--0.77   \<0.01       
  **Baseline CD4 count (cells/mm**^**3**^**)**   \<50                  51                        58.8   \<0.01                                       NI                         
  50--199                                        236                   47.9                                                                                                    
  200--349                                       257                   39.3                                                                                                    
  ≥350                                           782                   37.7                                                                                                    
  **Baseline HIV-1 RNA (cps/mL)**                \<50                  630                       32.5   \<0.01                                       1.00                       
  50--199                                        147                   48.3                             1.82                                         1.01--3.27   0.04         
  200--4,999                                     253                   51.4                             2.45                                         1.46--4.11   \<0.01       
  5.000--99,999                                  189                   39.7                             1.80                                         1.02--3.33   0.04         
  ≥100,000                                       120                   54.2                             2.98                                         1.67--6.03   \<0.01       
  **Drugs experienced (n)**                      \<3                   329                       36.5   0.11                                         NI                         
  3--6                                           345                   43.8                                                                                                    
  7--10                                          320                   47.8                                                                                                    
  ≥10                                            333                   39.9                                                                                                    
  **ART classes experienced, n **                1                     455                       36.9   0.01                                         NI                         
  2--3                                           926                   43.6                                                                                                    
  **Maraviroc daily dose**                       ≥300 mg               167                       50.9   \<0.01                                       0.72         0.49--1.06   0.09
  \<300 mg                                       992                   38.8                             1.00                                                                   
  **Maraviroc schedule**                         Once daily            276                       46.0   \<0.01                                       NI                         
  Twice daily                                    661                   38.6                                                                                                    
  **Context of maraviroc use**                   Naive                 46                        41.3   \<0.01                                       0.48         0.19--1.20   0.12
  Switch, suppressed VL                          409                   32.3                             1.00                                                                   
  Switch, detectable VL                          441                   49.0                             1.21                                         0.68--2.16   0.51         
  Intensify, suppressed VL                       50                    42.0                             1.52                                         0.79--2.94   0.21         
  Intensify, detectable VL                       50                    56.0                             1.42                                         0.63--3.23   0.40         
  **Previous PI experience**                     Yes                   1218                      42.9   0.04                                         1.62         1.05--2.48   0.03
  No                                             163                   30,7                             1.00                                                                   
  **Viral tropism**                              R5                    1061                      39.1   \<0.01                                       1.00                       
  Non-R5                                         165                   50.3                             1.65                                         1.20--2.27   \<0.01       
  **FPR**                                        ≤10                   51                        51.0   \<0.01                                       NI                         
  (10--20\]                                      68                    48.9                                                                                                    
  (20--40\]                                      156                   37.3                                                                                                    
  ≥40                                            330                   40.0                                                                                                    
  **GSS of accompanying regimen**                \<1                   83                        27.7   \<0.01                                       1.00                       
  1--2                                           254                   37.8                             1.33                                         0.64--2.76   0.34         
  2--3                                           228                   32.9                             1.08                                         0.52--2.26   0.69         
  ≥3                                             96                    55.2                             2.47                                         1.07--5.66   0.01         
  **Year of maraviroc start**                    ≥2012                 681                       60.9   \<0.01                                       3.20         2.39--4.30   \<0.01
  \<2012                                         127                   37.3                             1.00                                                                   

Note: Table refers to 1,381 subjects; cases with missing values for each variable are not reported in the table; in 264 cases viral tropism was collected but no FPR was available at the data analysis

NI: Not included in the final model

In the univariate analysis only variables with p-value \<0.20 are shown. Additional variables tested but not found to be associated (p ≥0.20) in univariate analysis comprised: gender, previous experience with NRTI, NNRTI, integrase inhibitors or enfuvirtide, and viral subtype.

^a^(≥ 35 vs \<35 years)

All variables shown in the univariate analysis were included in the multivariable model. Variables retained in the final step of the backward elimination procedure (see [methods](#sec006){ref-type="sec"}) are shown, all the other were excluded, except the viral tropism result than was manually included. All AOR shown are simultaneously adjusted. The FPR of the geno2pheno\[coreceptor\] genotypic tropism interpretation was not included in the multivariable model due to co-linearity with tropism result.

Of the 1,010 patients still on maraviroc at week 48, 201 (19.9%) had a viral load \>50 copies/mL, including 93 (9.2%) with levels between 50 and 200 copies/mL and 108 (10.7%) with levels \>200 copies/mL. The logistic regression analysis of factors associated with VF is shown in [Table 5](#pone.0225381.t005){ref-type="table"}. After adjustment, the odds of VF were increased by a low nadir CD4 count, a detectable baseline viral load, and having previously experienced PI therapy. There was also a marginal effect of age.

10.1371/journal.pone.0225381.t005

###### Univariate and multivariable logistic regression analysis of factors associated with virological failure at 48 weeks.
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                                        Univariate analysis   Multivariable analysis                                                                                 
  ------------------------------------- --------------------- ------------------------ ------ -------------------------------------------- ------------ ------------ ------
  Age (years)                           \<35                  105                      28.6   0.19                                         1.00                      0.05
  ≥35                                   897                   19.1                            0.58[^a^](#t005fn002){ref-type="table-fn"}   0.35--0.95                
  35--44                                354                   20.0                                                                                                   
  45--54                                379                   19.3                                                                                                   
  ≥55                                   164                   16.5                                                                                                   
  Nadir CD4 count (cells/mm^3^)         \<50                  195                      29.7   \<0.01                                       1.00                       
  50--199                               335                   17.9                            0.55                                         0.35--0.85   \<0.01       
  200--349                              209                   16.3                            0.57                                         0.34--0.94   0.03         
  ≥350                                  112                   14.3                            0.42                                         0.22--0.81   \<0.01       
  Baseline CD4 count (cells/mm^3^)      \<50                  31                       32.3   \<0.01                                       NI                         
  50--199                               170                   27.6                                                                                                   
  200--349                              196                   20.4                                                                                                   
  ≥350                                  584                   16.6                                                                                                   
  Baseline HIV-1 RNA (cps/mL)           \<50                  473                      10.1   \<0.01                                       1.00                       
  50--199                               110                   30.9                            3.59                                         2.13--6.03   \<0.01       
  200--4.999                            182                   32.4                            4.45                                         2.83--6.98   \<0.01       
  5.000--99.999                         141                   18.6                            2.37                                         1.39--4.03   \<0.01       
  ≥100.000                              81                    32.9                            4.88                                         2.74--8.69   \<0.01       
  Maraviroc daily dose                  \<300 mg              105                      21.9   0.33                                         NI                         
  ≥300 mg                               752                   19.3                                                                                                   
  Maraviroc schedule                    Once daily            190                      21.6   0.52                                         NI                         
  Twice daily                           498                   18.5                                                                                                   
  Context of maraviroc use              ART naive             32                       15.6   \<0.01                                       NI                         
  Switch. suppressed VL                 303                   8.6                                                                                                    
  Switch. detectable VL                 310                   27.7                                                                                                   
  Intensify. suppressed VL              34                    14.7                                                                                                   
  Intensify. detectable VL              37                    40.5                                                                                                   
  Drug classes previously experienced   \<3                   361                      17.2   0.13                                                                    
  3                                     337                   19.9                                                                                                   
  ≥3                                    311                   23.5                                                                                                   
  Previous PI experience                Yes                   876                      21.0   0.05                                         2.21         1.21--4.04   0.01
  No                                    133                   13.7                                                                                                   
  Previous INSTI experience             Yes                   *456*                    22.4   0.07                                         NI           * *          * *
  No                                    *553*                 17.9                                                                         * *          * *          
  Previous enfuvirtide experience       Yes                   *61*                     26.2   0.18                                         NI           * *          * *
  No                                    *948*                 19.5                                                                         * *          * *          
  Viral tropism                         R5                    805                      19.8   0.06                                         1.00                       
  Non-R5                                108                   25.2                            1.25                                         0.79--1.96   0.34         
  ART classes used with maraviroc (n)   1                     *378*                    15.9   0.02                                         NI           * *          * *
  2                                     *457*                 21.0                                                                         * *          * *          
  3                                     *105*                 28.6                                                                         * *          * *          
  Concomitant PI use                    Yes                   *655*                    21.3   0.17                                                      * *          * *
  No                                    *285*                 16.1                                                                         * *          * *          
  GSS of accompanying regimen           \<1                   73                       17.8   \<0.01                                       1.00                       
  1 \<2                                 191                   17.3                            0.82                                         0.64--2.76   0.61         
  2 \<3                                 188                   18.6                            0.86                                         0.40--1.85   0.69         
  ≥3                                    65                    33.8                            2.14                                         0.90--5.09   0.08         

Note: Table refers to 1009 subjects; cases with missing values for each variable are not reported in the table; in 264 cases viral tropism was collected but no FPR was available at the data analysis. Additional variables tested but not found to be associated by univariate analysis (p\>0.2): maraviroc schedule and daily dosing, gender, ethnicity, number of previous drugs experienced, previous experience with NRTIs, or NNRTIs, viral subtype, false positive rate value of the geno2pheno\[coreceptor\] genotypic tropism interpretation, and calendar year of maraviroc start.

^a^(≥ 35 vs \<35 years)

All variables shown in the univariate analysis were included in the multivariable model. Variables retained in the final step of the backward elimination procedure (see [methods](#sec006){ref-type="sec"}) are shown. all the other were excluded, except the viral tropism result that was manually included. All AOR shown are simultaneously adjusted.

Tables [6](#pone.0225381.t006){ref-type="table"} and [7](#pone.0225381.t007){ref-type="table"} show the outcomes for the relatively high number of subjects that received maraviroc outside of standard treatment guidelines. Overall, TF was more likely in subjects receiving maraviroc once daily, those receiving a total daily dose of 150mg and those with non-R5 tropism ([Table 6](#pone.0225381.t006){ref-type="table"}), whereas only non-R5 tropism showed a marginal effect on the occurrence of VF ([Table 7](#pone.0225381.t007){ref-type="table"}).

10.1371/journal.pone.0225381.t006

###### Univariate logistic regression analysis of the association between non-standard maraviroc uses and treatment failure.

![](pone.0225381.t006){#pone.0225381.t006g}

                          Treatment failure over 48 weeks                                               
  ----------------------- --------------------------------- ------ ------ ------ ------ ------ -------- --------
  Dosing schedule         Once daily                        149    54.0   127    46.0   276    \<0.01   0.01
  Twice daily             406                               61.4   255    38.6   661                    
  Unknown                 254                               57.2   190    42.8   444                    
                                                                                                         
  Total daily dose (mg)   150                               82     49.1   85     50.9   167    \<0.01   0.01
  300                     434                               59.2   299    40.8   733                    
  600                     153                               67.1   75     32.9   228                    
  1200                    20                                64.5   11     35.5   31                     
  ≥150                    607                               61.2   385    38.8   992                    
  Unknown                 120                               54.1   102    45.9   222                    
                                                                                                         
  Tropism                 R5                                643    61.3   406    38.7   1049   \<0.01   \<0.01
  Non-R5                  107                               47.8   117    52.2   224                    
  Unknown                 58                                53.7   50     46.3   108                    

Note: all p-values were calculated by a univariate mixed logistic model that takes into account the clustering effect of the clinical centre

\* p-value including unknown category

\*\* p-value excluding unknown category

10.1371/journal.pone.0225381.t007

###### Univariate logistic regression analysis of the association between non-standard maraviroc uses and virological failure.

![](pone.0225381.t007){#pone.0225381.t007g}

                          Virological failure (week 48)                                            
  ----------------------- ------------------------------- ------ ------ ------ ------ ----- ------ ------
  Dosing schedule         Once daily                      149    78.4   41     21.6   190   0.52   0.36
  Twice daily             406                             81.5   92     18.5   498                 
  Unknown                 254                             78.9   68     21.1   322                 
                                                                                                    
  Total daily dose (mg)   150                             82     78.1   23     21.9   105   0.45   0.33
  300                     434                             79.2   114    20.8   548                 
  600                     153                             84.5   28     15.5   181                 
  1200                    20                              87.0   3      13.0   23                  
  ≥150                    607                             80.7   145    19.3   752                 
  Unknown                 120                             78.4   33     21.6   153                 
                                                                                                    
  Tropism                 R5                              643    80.2   159    19.8   802   0.06   0.15
  Non-R5                  107                             74.8   36     25.2   143                 
  Unknown                 59                              90.8   6      9.2    65                  

Note: all p-values were calculated by a univariate mixed logistic model that takes into account the clustering effect of the clinical centre

\* p-value including unknown category

\*\* p-value excluding unknown category

Discussion {#sec016}
==========

This study reports the largest data set of maraviroc-containing treatment cases ever collected from routine clinical practice. We asked clinical sites to include all their patients initiating maraviroc outside clinical trials to assess the use and effectiveness of maraviroc across Europe, in a time frame spanning from 2005 to 2016. Based on this survey enrolling cases through 26 different clinical sites in 8 European countries, we observed that maraviroc was used in multiple clinical scenarios. Its most frequent use was as a switch therapy in highly ART-experienced patients with either detectable or undetectable viral load. In this population, maraviroc use was safe and reasonably effective. Maraviroc discontinuation was mostly due to VF, desire to simplify the treatment regimen, or issues of incomplete adherence with the regimen. Toxicity accounted for 18% of the reported reasons of maraviroc discontinuation. Clearly, neither toxicity nor VF could be specifically attributed to maraviroc, due to concomitant antiretrovirals. This being a retrospective study, it was not possible to investigate the details of the toxicity events and confirm their attribution to maraviroc or other drugs. Notably, only two cases of transaminase elevations were reported as reasons for maraviroc discontinuation. Major determinants of treatment failure--defined as discontinuation of maraviroc for any reason or virological failure--were the concomitant use of three or more predicted active drugs, and more recent calendar year of maraviroc initiation (after 2011). These findings are likely to reflect a higher propensity for maraviroc interruption in the presence of other active drugs, and the increased number of effective drugs that have become available in recent years.

Interestingly, a significant proportion (17.6%) of patients in the cohort started maraviroc despite carrying a non-R5 virus. Given that the classification as R5 was largely based on the centralised re-analysis of V3 sequences, the observed off-label use of maraviroc may in part reflect technical aspects of tropism testing and the application of different interpretation thresholds. There also appeared to be interest in exploring maraviroc activity in patients with mixed tropism results and in those for whom selective tissue activity was postulated (i.e., against virus replicating in the CNS-- 5 cases indeed reported this reason for maraviroc use). Non-R5 tropism predicted higher odds of treatment failure, however it had a weaker effect on virological failure, with a higher proportion of patients with non-R5 virus experiencing virological failure in a univariable analysis but no clear association in the adjusted model. This suggests that some of the non-standard use might have been explorative and short-term. In this context, tropism would not be expected to be the key predictor of virological failure. In addition, in the highly treatment-experienced population we analysed, multiple determinants are expected to impact virologic responses. There is evidence from the MOTIVATE trials of maraviroc in treatment-experienced patients that the composition of the overall regimen (alongside the baseline CD4 count) is a key predictor of virologic outcome, including in a small subset of patients with non-R5 virus \[[@pone.0225381.ref020]\].

About one in five patients on maraviroc had a detectable viral load after 48 weeks of follow-up. It should be noted that the analysis of virological failure excluded patients who either previously discontinued or were lost to follow-up, and that these may have comprised cases of virological failure. Although this may be considered a high rate of virological failure (when defined as a viral load \>50 copies/mL), interpretation should consider the high stringency applied to the definition of failure. Indeed, applying a higher and clinically more relevant viral load threshold of 200 copies/mL halved the number of virological failures, indicating that a substantial number of cases of viraemia were at low level. Moreover, the cohort had a significant history of treatment exposure with about two thirds of participants having previously experienced 3 or more antiretroviral drug classes. Predictors of virological failure were a low nadir CD4 cell count, a detectable viral load at maraviroc initiation, and a history of PI exposure, with a marginal effect of younger age. In line with these findings, previous cohort studies showed that older age reduces the risk of virological failure, likely as a result of improved medication adherence \[[@pone.0225381.ref021]\]. Higher baseline viral load and lower nadir CD4 counts were also associated with virological failure in other observational studies \[[@pone.0225381.ref022]--[@pone.0225381.ref024]\]. It should be noted that a low nadir CD4 count may indicate the presence minority CXCR4-tropic variants which would remain undetected by routine testing methods \[[@pone.0225381.ref025],[@pone.0225381.ref026]\]. The association of higher risk of virological failure with prior PI use may reflect circumstances associated with increased PI use including treatment failure, drug resistance and low medication adherence. Interestingly, we found no association between the activity of the regimen accompanying maraviroc (measured as the GSS) and virological failure. This implies that non-resistance related factors largely accounted for virological outcomes. For example, pre-treated patients with high GSS values may actually reflect past failures due to non-adherence to therapy. On the other hand, in a population with extensive treatment experience, the extent of archived drug resistance and residual drug activity despite resistance may both be underestimated \[[@pone.0225381.ref027]\].

The treatment collection included several cases of non-standard, off-label maraviroc use. Indeed, it included ART-naïve subjects (unlicensed indication in Europe), patient carrying non-R5 virus, and cases with once-daily maraviroc dosing and low daily doses of 150mg. While we cannot exclude prescription errors, it is also realistic to assume that the drug was deliberately used in off-label indications. Off-label use may result from lack of alternative treatment options because of toxicity or drug resistance, hypothesised residual drug activity \[[@pone.0225381.ref028]\], or the need for dosing simplification to once-daily regimens and lower drug dosing as suggested by pharmacokinetics reports, in association with boosted PI \[[@pone.0225381.ref029]\]. Overall, we found evidence that using maraviroc either once daily, at a low total daily dose of 150mg, or with non-R5 virus increased the likelihood of treatment failure, but the effect on virological failure was only marginally apparent with non-R5 virus. One relatively common use of maraviroc was treatment intensification due to low CD4 cell counts. This reflects prior evidence of an immunologic benefit of maraviroc use, independent from its antiviral efficacy, which was not confirmed by subsequent controlled studies \[[@pone.0225381.ref030],[@pone.0225381.ref031]\].

This study has several limitations. First, no measure of medication adherence was available, therefore this major determinant of treatment outcome could not be analysed. This is not different from the majority of other reported observational studies of ART outcomes, which did not collect medication adherence systematically and could not adjust for this factor. Second, some variables such as genotypic susceptibility of the concomitant regimen and viral subtype were not available for a large proportion of cases, therefore their predictive value could not be fully analysed. Third, the retrospective design of the study did not allow to confirm the reasons for maraviroc initiation or interruption. In order to partly overcome this limitation, we used objective data such as the pre-treatment viral load, the pre-maraviroc treatment regimen, and the drugs prescribed concomitantly with maraviroc to classify the different clinical scenarios of maraviroc prescription. Despite these limitations, this study is unique in depicting the clinical use of maraviroc in clinical practice throughout Western Europe during the last decade.

In conclusion, in this large European survey we found that maraviroc was used in multiple clinical scenarios involving mostly ART-experienced patients, both virologically suppressed and with detectable viremia. In a population of highly experienced patients, maraviroc was overall safe and reasonably effective, also when considering that there was a considerable use of exploratory off label treatments, and a substantial number of virological failures occurred at viral load \<200 copies/mL. High discontinuation rates in recent years presumably reflected the availability of alternative active agents. In current guidelines, maraviroc continues to represent a valid antiretroviral option in selected patients, particularly those with limited drug options or intolerance to agents from other classes. The virological rationale for using CCR5 antagonists early in therapy is still strong, as reflected by the significant impact of a low nadir CD4 count on treatment outcomes \[[@pone.0225381.ref032]\]. Whether CCR5 antagonists exhibit additional benefits beyond their antiviral activity remains to be established \[[@pone.0225381.ref033]--[@pone.0225381.ref035]\].

This manuscript is dedicated to the memory of our beloved colleagues Andrea De Luca and Eugen Schülter, who contributed greatly to the work presented and too soon passed away.
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